Objective: Estimate the time-course of the spread of key pathological markers and the onset of cognitive dysfunction in Alzheimer's disease. Methods: In a cohort of 335 older adults, ranging in cognitive functioning, we estimated the time of initial changes of Aβ, tau, and decreases in cognition with respect to the time of Aβ-positivity. Results: Small effect sizes of change in CSF Aβ42 and regional Aβ PET were estimated to occur several decades before Aβ-positivity. Increases in CSF tau occurred 7–8 years before Aβ-positivity. Temporoparietal tau PET showed increases 4–5 years before Aβ-positivity. Subtle cognitive dysfunction was observed 4–6 years before Aβ-positivity. Conclusions: Increases in tau and cognitive dysfunction occur years b...
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the disease p...
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the disease p...
OBJECTIVES: Amyloid-beta (Aβ) and tau pathologies are commonly observed among clinically normal olde...
Background: Aβ pathology is associated with longitudinal changes of brain metabolism, atrophy, and c...
Background: Aβ pathology is associated with longitudinal changes of brain metabolism, atrophy, and c...
With recent advances in our understanding of the continuous pathophysiological changes that begin ma...
The elusive relationship between underlying pathology and clinical disease hampers diagnosis of Alzh...
Objective: To estimate points along the spectrum of β-amyloid pathology at which rates of change of ...
Using positron emission tomography (PET)-derived amyloid and tau measurements from 1,495 participant...
Background: We investigated the pattern of disease progression in the asymptomatic, mild cognitive i...
Introduction: Amyloid beta (Aβ) deposition was identified to precede tau pathology and neurodegenera...
CONTEXT: Early detection of prodromal Alzheimer disease (AD) is important because new disease-modify...
Background: We investigated the pattern of disease progression in the asymptomatic, mild cognitive i...
Background: We investigated the pattern of disease progression in the asymptomatic, mild cognitive i...
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the disease p...
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the disease p...
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the disease p...
OBJECTIVES: Amyloid-beta (Aβ) and tau pathologies are commonly observed among clinically normal olde...
Background: Aβ pathology is associated with longitudinal changes of brain metabolism, atrophy, and c...
Background: Aβ pathology is associated with longitudinal changes of brain metabolism, atrophy, and c...
With recent advances in our understanding of the continuous pathophysiological changes that begin ma...
The elusive relationship between underlying pathology and clinical disease hampers diagnosis of Alzh...
Objective: To estimate points along the spectrum of β-amyloid pathology at which rates of change of ...
Using positron emission tomography (PET)-derived amyloid and tau measurements from 1,495 participant...
Background: We investigated the pattern of disease progression in the asymptomatic, mild cognitive i...
Introduction: Amyloid beta (Aβ) deposition was identified to precede tau pathology and neurodegenera...
CONTEXT: Early detection of prodromal Alzheimer disease (AD) is important because new disease-modify...
Background: We investigated the pattern of disease progression in the asymptomatic, mild cognitive i...
Background: We investigated the pattern of disease progression in the asymptomatic, mild cognitive i...
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the disease p...
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the disease p...
Background and Objectives Alzheimer disease (AD) clinical trials are moving earlier in the disease p...
OBJECTIVES: Amyloid-beta (Aβ) and tau pathologies are commonly observed among clinically normal olde...